IP for Licensing

  1. Predictive diagnostic molecular biomarkers and therapeutic targets
    • Obesity
    • Type 2 diabetes
    • Hypertension
    • Atherosclerosis, coronary heart disease, cerebrovascular disease
    • Alcohol addiction
  2. Nutrigenetic biomarkers
    • Benefits/harms of vitamin E
    • Weight increasing effects of dietary fats, carbohydrates
  3. Specific therapeutics
    • Vitamin D and a compound that enhances the healthy effects of vitamin D
    • L-cysteine in cardiovascular and metabolic indications

For all IP

Funding and Commercialization

  • MAS Oy are offering to license out the invention at an early phase against up-front payment, milestones and royalty
  • Alternatively, MAS will take on board a partner, which would either
    • License the invention from MAS and contract MAS to develop it or
    • Co-fund the development work with MAS Oy, with TEKES (Finnish government) etc participating on the basis or exclusive option rights or right of first refusal to the invention

Opportunity for a Diagnostics, Pharma, Biotechnology or Consumer Genetics Company

  • a diagnostics company may develop an IVD product for global markets
  • a drug or biotechnology company may develop therapeutics (biologicals, small molecules or gene therapy) on the basis of the target information
  • a consumer genetics company or CLIA laboratory may offer genetic testing services for consumers globally